Alimera Sciences Inc (ALIM)
1.36
-0.06
(-4.23%)
USD |
NASDAQ |
Mar 24, 16:00
1.36
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 9.532M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -76.33% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.1757 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -2.423 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.17% |
News
Headline
Wire
Time (ET)
Yahoo
03/24 16:05
Globe Newswire
02/22 08:00
Yahoo
01/09 08:00
Globe Newswire
01/09 08:00
Globe Newswire
12/08 08:00
Globe Newswire
11/29 08:00
MT Newswires
11/21 09:25
MT Newswires
11/14 07:33
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/09/2023* | 09:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/09/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 11/14/2022 | 09:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/14/2022 | -- | Results | Q3 2022 | -0.69 | -0.37 | -85.92% | |
| 07/27/2022 | -- | Results | Q2 2022 | -0.47 | -0.53 | 11.26% | |
| 07/27/2022 | 09:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/09/2022 | 09:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.79 | -0.62 | -27.78% |
*Estimated Date/Time
Earnings
Profile
Edit
| Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU. |
| URL | https://www.alimerasciences.com |
| Investor Relations URL | http://investor.alimerasciences.com/index.cfm |
| HQ State/Province | Georgia |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 54.06M |
| Total Expenses (TTM) | 66.34M |
| Net Income (TTM) | -18.43M |
| Total Assets (Quarterly) | 43.43M |
| Total Liabilities (Quarterly) | 61.51M |
| Shareholders Equity (Quarterly) | -18.08M |
| Cash from Operations (TTM) | -14.41M |
| Cash from Investing (TTM) | -0.292M |
| Cash from Financing (TTM) | -0.128M |
Ratings
Profile
Edit
| Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU. |
| URL | https://www.alimerasciences.com |
| Investor Relations URL | http://investor.alimerasciences.com/index.cfm |
| HQ State/Province | Georgia |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ALIM Tweets |